Shilanski & Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Shilanski & Associates’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,654	Closed	-$326K	–	93
2020 Q2	$326K	Buy	1,654 +74	+5%	+$15.3K	0.24%	69
2020 Q1	$310K	Buy	1,580 +54	+4%	+$11.6K	0.31%	64
2019 Q4	$316K	Sell	1,526 -21	-1%	-$3.88K	0.24%	69
2019 Q3	$236K	Sell	1,547 -70	-4%	-$11.5K	0.19%	75
2019 Q2	$208K	Buy	+1,617	New	+$192K	0.17%	80

Other funds holding LKFT

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Shilanski & Associates's LKFT Position: Q3 2020 in Review

Shilanski & Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2020, closing a stake of 1,654 shares — an estimated $326K sold.

Shilanski & Associates first reported a position in LKFT in Q2 2019 and held it in 5 quarters. The position peaked at $326K in Q2 2020. 119 funds tracked by Wall St. Rank hold LKFT as of Q3 2020.

Shilanski & Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2020 after selling out during the quarter.
Shilanski & Associates sold 1,654 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2020, an estimated $326K.
Shilanski & Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2019 and held it in 5 quarters.
Shilanski & Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $326K in Q2 2020.
119 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2020.

Based on Shilanski & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.